{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T01:39:02Z","timestamp":1792028342071,"version":"4.4.0"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,8,12]],"date-time":"2022-08-12T00:00:00Z","timestamp":1660262400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>The effect of primary site on cardiovascular mortality (CVM) post-radiotherapy (RT) in patients with limited-stage small cell lung cancer (LS-SCLC) remains unclear.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We screened the Surveillance, Epidemiology, and End Results (SEER) database between 1988 and 2013. We used cumulative incidence function (CIF) curves to compare CVM incidences, and performed Cox proportional hazards and Fine-Gray competing risk analyses to identify independent risk factors of CVM. Propensity score matching (PSM) analysis was conducted.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among enrolled 4,824 patients (median age 57 years old, 49.2% were male), CVM accounts for 10.0% of all deaths after 5 years since cancer diagnosis. Hazard ratios (HRs) for CVM were 1.97 (95% CI: 1.23\u20133.16, <jats:italic>P<\/jats:italic> = 0.005) for main bronchus (MB) patients, 1.65 (95% CI: 1.04\u20132.63, <jats:italic>P<\/jats:italic> = 0.034) for lower lobe (LL) patients and 1.01 (95% CI: 0.40\u20132.59, <jats:italic>P<\/jats:italic> = 0.977) for middle lobe (ML) patients compared to upper lobe (UL) patients. CIF curves showed that the cumulative CVM incidence was greater in the re-categorized MB\/LL group compared to UL\/ML group both before PSM (<jats:italic>P<\/jats:italic> = 0.005) and after PSM (<jats:italic>P<\/jats:italic> = 0.012). Multivariate regression models indicated that MB\/LL was independently associated with an increased CVM risk, before PSM (HR<jats:sub>Cox<\/jats:sub>: 1.79, 95% CI: 1.23\u20132.61, <jats:italic>P<\/jats:italic> = 0.002; HR<jats:sub>Fine\u2212Gray<\/jats:sub>: 1.71, 95% CI: 1.18\u20132.48, <jats:italic>P<\/jats:italic> = 0.005) and after PSM (HR<jats:sub>Cox<\/jats:sub>: 1.88, 95% CI: 1.20\u20132.95, <jats:italic>P<\/jats:italic> = 0.006; HR<jats:sub>Fine\u2212Gray<\/jats:sub>: 1.79, 95% CI: 1.15\u20132.79, <jats:italic>P<\/jats:italic> = 0.010).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>MB\/LL as the primary site is independently associated with an increased CVM risk post-RT in patients with LS-SCLC.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fcvm.2022.922811","type":"journal-article","created":{"date-parts":[[2022,8,12]],"date-time":"2022-08-12T05:49:27Z","timestamp":1660283367000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Primary site as a novel prognostic factor for cardiovascular mortality post-radiotherapy in limited-stage small cell lung cancer: A large population-based study"],"prefix":"10.3389","volume":"9","author":[{"given":"Yuwei","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fen","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingqi","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wuyan","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,8,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","article-title":"2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC committee for practice guidelines: the task force for cancer treatments and cardiovascular toxicity of the European society of cardiology (ESC)","volume":"37","author":"Zamorano","year":"2016","journal-title":"Eur Heart J."},{"key":"B2","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1016\/j.jacc.2019.07.006","article-title":"Prevention, diagnosis, and management of radiation-associated cardiac disease: JACC scientific expert panel","volume":"74","author":"Desai","year":"2019","journal-title":"J Am Coll Cardiol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa1209825","article-title":"Risk of ischemic heart disease in women after radiotherapy for breast cancer","volume":"368","author":"Darby","year":"2013","journal-title":"N Engl J Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.jacbts.2018.01.014","article-title":"Radiation-Induced endothelial vascular injury: a review of possible mechanisms","volume":"3","author":"Venkatesulu","year":"2018","journal-title":"JACC Basic Transl Sci."},{"key":"B5","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/clc.22631","article-title":"Long-term cardiovascular mortality after radiotherapy for breast cancer: a systematic review and meta-analysis","volume":"40","author":"Sardar","year":"2017","journal-title":"Clin Cardiol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1182\/blood-2016-09-740332","article-title":"Risk of heart failure in survivors of hodgkin lymphoma: effects of cardiac exposure to radiation and anthracyclines","volume":"129","author":"van Nimwegen","year":"2017","journal-title":"Blood."},{"key":"B7","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1093\/annonc\/mdt156","article-title":"Estimated risk of cardiovascular disease and secondary cancers with modern highly conformal radiotherapy for early-stage mediastinal hodgkin lymphoma","volume":"24","author":"Maraldo","year":"2013","journal-title":"Ann Oncol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21590","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J Clin."},{"key":"B9","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1002\/cncr.22845","article-title":"The risk of death from heart disease in patients with nonsmall cell lung cancer who receive postoperative radiotherapy: analysis of the surveillance, epidemiology, and end results database","volume":"110","author":"Lally","year":"2007","journal-title":"Cancer-Am Cancer Soc."},{"key":"B10","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/S1470-2045(14)71207-0","article-title":"Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study","volume":"16","author":"Bradley","year":"2015","journal-title":"Lancet Oncol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1200\/JCO.2016.71.6142","article-title":"Cardiac events after radiation therapy: combined analysis of prospective multicenter trials for locally advanced Non-Small-Cell lung cancer","volume":"35","author":"Dess","year":"2017","journal-title":"J Clin Oncol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1200\/JCO.2016.70.0229","article-title":"Cardiac toxicity after radiotherapy for stage III non-small-cell lung cancer: pooled analysis of dose-escalation trials delivering 70 to 90 Gy","volume":"35","author":"Wang","year":"2017","journal-title":"J Clin Oncol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.ijrobp.2017.10.031","article-title":"Trends in cardiac mortality in patients with locally advanced non-small cell lung cancer","volume":"100","author":"Haque","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"B14","doi-asserted-by":"publisher","first-page":"2976","DOI":"10.1016\/j.jacc.2019.03.500","article-title":"Cardiac radiation dose, cardiac disease, and mortality in patients with lung cancer","volume":"73","author":"Atkins","year":"2019","journal-title":"J Am Coll Cardiol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1056\/NEJM199212033272302","article-title":"A meta-analysis of thoracic radiotherapy for small-cell lung cancer","volume":"327","author":"Pignon","year":"1992","journal-title":"N Engl J Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1016\/S1470-2045(17)30318-2","article-title":"Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): An open-label, phase 3, randomised, superiority trial","volume":"18","author":"Faivre-Finn","year":"2017","journal-title":"Lancet Oncol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s13045-019-0736-3","article-title":"Emerging therapies for small cell lung cancer","volume":"12","author":"Yang","year":"2019","journal-title":"J Hematol Oncol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"2819","DOI":"10.2217\/fon-2019-0098","article-title":"Poor survival of non-small-cell lung cancer patients with main bronchus tumor: a large population-based study","volume":"15","author":"Li","year":"2019","journal-title":"Future Oncol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.lungcan.2018.03.011","article-title":"Main bronchus location is a predictor for metastasis and prognosis in lung adenocarcinoma: a large cohort analysis","volume":"120","author":"Yang","year":"2018","journal-title":"Lung Cancer."},{"key":"B20","doi-asserted-by":"publisher","first-page":"e49","DOI":"10.1016\/j.cllc.2016.06.002","article-title":"Primary tumor location is a useful predictor for lymph node metastasis and prognosis in lung adenocarcinoma","volume":"18","author":"Sun","year":"2017","journal-title":"Clin Lung Cancer."},{"key":"B21","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.ijrobp.2017.02.227","article-title":"Lung and heart dose variability during radiation therapy of non-small cell lung cancer","volume":"98","author":"Jan","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1001\/jama.270.16.1949","article-title":"Factors affecting late mortality from heart disease after treatment of Hodgkin's disease","volume":"270","author":"Hancock","year":"1993","journal-title":"JAMA."},{"key":"B23","doi-asserted-by":"publisher","first-page":"2936","DOI":"10.1093\/eurheartj\/ehu131","article-title":"Competing risks analyses: objectives and approaches","volume":"35","author":"Wolbers","year":"2014","journal-title":"Eur Heart J."},{"key":"B24","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.cjca.2015.05.015","article-title":"A review of propensity-score methods and their use in cardiovascular research","volume":"32","author":"Deb","year":"2016","journal-title":"Can J Cardiol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1002\/sim.5984","article-title":"The use of propensity score methods with survival or time-to-event outcomes: Reporting measures of effect similar to those used in randomized experiments","volume":"33","author":"Austin","year":"2014","journal-title":"Stat Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.ijrobp.2018.05.066","article-title":"Radiation therapy is associated with an increased incidence of cardiac events in patients with small cell lung cancer","volume":"102","author":"Ferris","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"B27","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.radonc.2018.06.011","article-title":"Cardiac mortality in limited-stage small cell lung cancer","volume":"128","author":"Verma","year":"2018","journal-title":"Radiother Oncol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s11748-004-0069-0","article-title":"Radiotherapy-induced aortic valve disease associated with porcelain aorta","volume":"52","author":"Daitoku","year":"2004","journal-title":"Jpn J Thorac Cardiovasc Surg."},{"key":"B29","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/0002-9343(81)90574-X","article-title":"Radiation heart disease. analysis of 16 young (aged 15 to 33 years) necropsy patients who received over 3,500 rads to the heart","volume":"70","author":"Brosius","year":"1981","journal-title":"Am J Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"477","DOI":"10.2214\/ajr.147.3.477","article-title":"Calcified ascending aorta after radiation therapy","volume":"147","author":"Coblentz","year":"1986","journal-title":"AJR Am J Roentgenol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1016\/j.canrad.2019.05.016","article-title":"Illustration of a fatal radiation-induced lung aneurysm: is central lung stereotactic radiotherapy to be banned?","volume":"23","author":"Ledoux","year":"2019","journal-title":"Cancer Radiother."},{"key":"B32","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1007\/s10552-018-1057-5","article-title":"Using hospital medical record data to assess the accuracy of the SEER Los Angeles cancer surveillance program for initial treatment of prostate cancer: a small pilot study","volume":"29","author":"Kraus","year":"2018","journal-title":"Cancer Causes Control."}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2022.922811\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,12]],"date-time":"2022-08-12T05:49:30Z","timestamp":1660283370000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2022.922811\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,12]]},"references-count":32,"alternative-id":["10.3389\/fcvm.2022.922811"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2022.922811","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,12]]},"article-number":"922811"}}